INTEGRA LIFESCIENCES HOLDINGS Business Summary

Integra LifeSciences Holdings Corp is a global leader in medical technology, generating revenue primarily through the direct sale of specialized surgical instruments, neurosurgical devices, and regenerative tissue implants. The company operates through two primary business segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment, which contributes approximately 70% of total revenue, focuses on neurosurgery, neurocritical care, and otolaryngology, recently bolstered by the strategic integration of Acclarent. The TT segment provides advanced solutions for wound repair, surgical reconstruction, and peripheral nerve repair using proprietary collagen matrix technology. In the competitive landscape, Integra contends with diversified giants such as Medtronic, Stryker, Johnson & Johnson (DePuy Synthes), and Boston Scientific. While smaller in scale than these conglomerates, Integra maintains a dominant niche position as a pure-play leader in neurosurgical tools and advanced bio-implants, currently scaling its manufacturing capacity through the 2026 operationalization of its state-of-the-art Braintree facility. Founded in 1989 by Dr. Richard E. Caruso, the company is currently led by President and CEO Mojdeh Poul, who assumed the role in January 2025. Poul brings over 30 years of healthcare experience, including a significant tenure as Executive Vice President at 3M, where she managed an $8.5 billion global healthcare portfolio. The executive team includes CFO Lea Daniels Knight, a veteran of Johnson & Johnson and Baxter, and Chief Medical Officer Dr. Raymond Turner, appointed in late 2025 to lead worldwide medical affairs and clinical development. The leadership is overseen by Executive Chairman Stuart Essig, a transformative figure who served as CEO for over a decade and continues to guide the company’s inorganic growth strategy. Notable institutional investors include BlackRock, Vanguard, and T. Rowe Price, reflecting sustained confidence in Integra’s specialized portfolio and its pivot toward high-margin regenerative technologies.